FDA grants accelerated approval to Rybrevant Faspro for recurrent head and neck cancer

The Food and Drug Administration on November 5, 2026 granted accelerated approval to Rybrevant Faspro, a subcutaneous product combining amivantamab with hyaluronidase-lpuj, according to an FDA approval notice posted November 6 and an agency press release issued November 5 ^[1][2]. The approval went to Janssen Biotech, Inc. ^[1]. The indication covers adults whose head and neck squamous cell carcinoma (HNSCC) has come back or spread, and whose cancer kept growing during or after treatment with platinum chemotherapy and an anti-PD-(L)1 antibody ^[1].

The label leaves out one group of patients. The FDA said the product is not indicated for people whose oropharyngeal squamous cell carcinoma (OPSCC) is linked to human papillomavirus (HPV) ^[1][2].

The press release described the decision as "the first approval in 10 years of a drug" for patients in this previously treated population ^[2]. Angelo De Claro, M.D., director of the FDA's Oncology Center of Excellence, said in the release that HNSCC is "a disease where treatment options have historically been limited and outcomes remain poor" ^[2].

What the records show

The FDA based the approval on OrigAMI-4 (NCT06385080), described in the approval notice as a multicenter, open-label, multi-cohort trial ^[1]. The primary efficacy population was 102 patients with recurrent or metastatic HNSCC ^[1]. Patients with HPV-associated OPSCC, identified by p16 testing, were not part of that population ^[1]. Everyone enrolled had to have prior treatment with both platinum chemotherapy and an anti-PD-(L)1 antibody ^[1].

Patients got the drug alone, dosed by body weight, as a subcutaneous injection once every 3 weeks ^[1]. Treatment continued until the cancer progressed or side effects became unacceptable ^[1].

The main outcome measures were overall response rate (ORR) and duration of response (DOR), judged by blinded independent central review using RECIST v1.1 ^[1]. Results, per the notice:

• ORR was 42% (95% CI: 32%, 52%) ^[1].
• Among responders, 56% had a response lasting 6 months or more ^[1].

The press release said currently approved options in this setting carry a response rate "of around 20% or less" ^[2]. It also said the trial showed "more than double the percentage of patients responded to the drug" compared with existing therapies ^[2].

The single-agent prescribing information carries warnings and precautions in five areas, according to both records: reactions tied to hypersensitivity or to administration of the drug, interstitial lung disease or pneumonitis, skin-related adverse reactions, eye toxicity, and harm to a developing fetus ^[1][2].

The recommended dose depends on body weight, and the notice directs readers to the prescribing information for specifics ^[1]. The notice said the full prescribing information "will be posted on Drugs@FDA" ^[1].

The review ran under Project Orbis, an Oncology Center of Excellence program that lets international regulators submit and review oncology drugs at the same time ^[1]. For this product, the FDA worked with the Brazilian Health Regulatory Agency (ANVISA), Health Canada, the Israel Ministry of Health and Singapore's Health Sciences Agency ^[1]. The application had priority review and breakthrough therapy designation, and the sponsor submitted a voluntary Assessment Aid ^[1][2].

Why it matters for clinicians

The patients covered by this label have already been through platinum chemotherapy and immunotherapy for a cancer that has recurred or spread ^[1][2]. The press release called HNSCC "an aggressive, life-threatening disease" with a high unmet need ^[2]. Clinicians who see these patients in emergency or prehospital settings may now encounter a new subcutaneous agent given on a 3-week cycle ^[1].

The labeled warnings describe problems that can present acutely. They include hypersensitivity and administration-related reactions, lung inflammation in the form of interstitial lung disease or pneumonitis, skin reactions and eye toxicity ^[1][2]. The records do not report how often each occurred in the trial.

The FDA asks healthcare professionals to report suspected serious adverse events to its MedWatch Reporting System or by calling 1-800-FDA-1088 ^[1]. EMS clinicians follow local protocols and medical direction.

Context

Accelerated approval is an FDA pathway for drugs that treat serious conditions and address an unmet need, with approval resting on surrogate or intermediate endpoints rather than proven long-term benefit ^[2]. Here, the endpoints were response rate and duration of response ^[2]. Because it is "not yet confirmed" that those results will translate into meaningful long-term benefit, the FDA said it has required confirmatory studies ^[2].

Amivantamab and hyaluronidase-lpuj was studied as a single agent in this trial, and the notice says the warnings apply to single-agent use ^[1].

What the records do not tell us

• Neither record reports survival data, progression-free survival or how long patients were followed ^[1][2].
• The specific weight-based doses are not in either record; the notice refers readers to prescribing information that had not yet been posted when the notice was written ^[1].
• Rates of individual adverse reactions in the trial are not given ^[1][2].
• The FDA said confirmatory studies are required but did not name them or give a timeline ^[2].
• The records do not say whether ANVISA, Health Canada, Israel or Singapore have approved the product; the notice says those applications may still be in submission or under review ^[1].
• No statement from Janssen Biotech, and no pricing or availability date, appears in the packet.

What to watch

The FDA said full prescribing information for Rybrevant Faspro will be posted on Drugs@FDA ^[1]. The agency has required confirmatory studies to verify clinical benefit, and decisions from the four partner regulators in the Project Orbis review may follow ^[1][2].

This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.